Progyny, Inc. filings document public-company reporting for its Nasdaq-listed common stock and its women's health and family building benefits business. Recent Form 8-K reports furnish quarterly and annual financial results, guidance updates, Regulation FD materials, supplemental earnings presentations, and other material-event disclosures.
The company's proxy materials cover annual meeting governance, director and executive compensation, equity award information, and related shareholder voting matters. Other filings address executive employment and compensatory arrangements, as well as a derivative-action settlement notice tied to historical non-employee director compensation practices.
Allison C. Swartz submitted a Form 144 notice reporting proposed transactions in common stock tied to restricted stock vesting as compensation. The filing lists 2,199 shares in the securities table and records a prior sale of 530 shares on 12/04/2025.
Progyny, Inc. files its annual report describing a fast‑growing women’s health and family building benefits platform. The company serves more than 590 self‑insured employers across over 40 industries, covering about 7.2 million employees and dependents through fertility, pharmacy, pregnancy, menopause and family support solutions.
Progyny highlights its proprietary Smart Cycle plan design, integrated Progyny Rx pharmacy benefit, selective Center of Excellence fertility network and concierge care advocates, which it says drive higher live birth rates and fewer multiple births than national averages. The filing also outlines extensive regulatory, competitive, macroeconomic, data privacy and technology (including AI) risks that could affect future growth and profitability.
Progyny, Inc. reported record 2025 results and raised its outlook for 2026. Full-year 2025 revenue reached $1,288.7 million, up 10% from 2024, or 20% excluding a large former client under a transition agreement. Gross profit rose 20% to $304.5 million, lifting gross margin to 23.6%.
Net income for 2025 was $58.5 million, or $0.65 per diluted share, with Adjusted EBITDA of $222.1 million and a 17.2% Adjusted EBITDA margin. Operating cash flow hit a record $210.2 million. As of December 31, 2025, Progyny had $310.1 million in cash and marketable securities, $349.4 million of working capital, and no debt.
In the fourth quarter, revenue was $318.4 million, up 6.7% year over year, or 21% excluding the former client, while gross margin expanded to 24.1%. The company repurchased 3.3 million shares for $83.6 million in the quarter and about 6.5 million shares to date, spending roughly $160 million under its $200 million authorization.
For 2026, Progyny projects revenue of $1.355 billion to $1.405 billion, net income of $95.4 million to $106.1 million (or $1.10 to $1.22 per diluted share), Adjusted EBITDA of $224.0 million to $239.0 million, and continued revenue growth excluding the transitioned client.
Progyny, Inc. furnished an update to its previously issued financial guidance for the three months and full year ending December 31, 2025. The company did this by issuing a press release dated January 12, 2026, which is attached as Exhibit 99.1 to this Form 8-K and incorporated by reference into the disclosure under Item 2.02. The information in this item and the exhibit is being furnished rather than filed under securities laws, meaning it is not subject to certain liability provisions and is not automatically incorporated into other regulatory documents.
Progyny, Inc. announced that the employment of its President, Michael Sturmer, will end effective December 31, 2025, with severance provided under his existing 2021 employment agreement. The company is not appointing a new President, noting that it has strengthened its executive team with recent hires in commercial, technology, operations and product leadership roles.
To support continuity on key projects and strategic initiatives, Sturmer will remain as a non-employee consultant through December 31, 2026, under a new consulting agreement. He will receive an annual advisory fee of $250,000, and if he continues to serve through June 30, 2026, his outstanding and vested stock options will have their exercisability extended proportionally to the period of consulting services. The full consulting agreement will be filed as an exhibit to Progyny’s Annual Report on Form 10-K for the year ending December 31, 2025.
Progyny, Inc. reported an insider stock transaction by its chief financial officer, Mark S. Livingston. On December 11, 2025, he sold 459 shares of Progyny common stock at $25.5 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan that was entered into on August 15, 2025. Following this transaction, he directly owns 46,983 shares of Progyny common stock.
Progyny, Inc.'s president reported a routine equity compensation-related share withholding. On 12/04/2025, 7,977 shares of common stock were withheld at $24.55 per share to pay withholding taxes triggered by the vesting of restricted stock units granted to the officer. After this transaction, the president directly beneficially owned 288,233 Progyny shares.
Progyny, Inc. (PGNY) reported an insider stock sale by its Chief Financial Officer. On 11/17/2025, the CFO sold 21,303 shares of Progyny common stock at a price of $25.50 per share, as shown in Table I of the filing. After this transaction, the CFO beneficially owns 48,358 shares of common stock in a direct capacity.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that was entered into on August 15, 2025. These plans allow insiders to systematically sell shares according to preset instructions, helping separate personal liquidity decisions from day-to-day company developments.
Progyny, Inc. (PGNY) director reported an option exercise and a share transfer. On 11/14/2025, the reporting person exercised a stock option for 36,224 shares of common stock at $1.45 per share, paying the exercise price in cash and holding all shares received, with no shares sold in connection with the exercise.
On 11/18/2025, the reporting person transferred 50,265 shares held directly to The Norman C. and Melinda B. Payson Revocable Trust for no consideration, reported as a gift. Following these transactions, the person held common stock directly and also indirectly through the revocable trust and through EVO Eagle, LLC, over which the reporting person shares voting and dispositive power.
Progyny, Inc. (PGNY) disclosed that its Chief Executive Officer and director purchased 79,500 shares of common stock on 11/13/2025. The shares were bought at a weighted average price of $24.288 per share, in multiple trades at prices ranging from $23.73 to $24.52. Following this transaction, the reporting person beneficially owns 680,251 shares directly and an additional share indirectly through PECO ANEVSKI 2020 SD LLC. The filing notes that the purchase was made to offset a tax withholding obligation arising from the net settlement of performance stock units reported the same day.